• gastrointestinal_900x400_2017-950x280.jpg

    Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

    13 May, 2020
    The prevalence and prognosis of digestive system involvement, including gastrointestinal symptoms and liver injury, in patients with COVID-19 remains largely unknown. We aimed to quantify the effects of COVID-19 on the digestive system.
    In this systematic review and meta-analysis, we systematically searched PubMed, Embase, and Web of Science for studies published between Jan 1, 2020, and April 4, 2020. The websites of WHO, CDC, and major journals were also searched. We included studies t...
  • efcb1b96-9110-11ea-a674-527cfdef49ee_image_hires_051230.jpeg

    Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

    12 May, 2020
    Among patients with coronavirus disease 2019 (COVID-19), is there an association between use of hydroxychloroquine, with or without azithromycin, and in-hospital mortality?

    In a retrospective cohort study of 1438 patients hospitalized in metropolitan New York, compared with treatment with neither drug, the adjusted hazard ratio for in-hospital mortality for treatment with hydroxychloroquine alone was 1.08, for azithromycin alone was 0.56, and...
  • Nature.png

    The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

    11 May, 2020

    Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the corona virus disease 2019 (COVID-19) cases in China and has become a public health emergency of international concern1. Because angiotensin-converting enzyme 2 (ACE2) is the cell entry receptor of SARS-CoV5, we used transgenic mice bearing human ACE2 and infected with SARS-CoV-2 to study the pathogenicity of the virus. Weight loss and virus replication in lung were observed in hACE2 mice infected with SARS-CoV-2. The typical ...
  • The_lancet.png

    Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

    11 May, 2020
    Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19. This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir ...
  • new-vitamin-d.jpg

    Vitamin D levels appear to play role in COVID-19 mortality rates

    8 May, 2020
    After studying global data from the novel coronavirus (COVID-19) pandemic, researchers have discovered a strong correlation between severe vitamin D deficiency and mortality rates.

    Led by Northwestern University, the research team conducted a statistical analysis of data from hospitals and clinics across China, France, Germany, Italy, Iran, South Korea, Spain, Switzerland, the United Kingdom (UK) and the United States.

    The researchers noted that patients from countries with high...
  • unnamed.png

    Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

    8 May, 2020
    Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1 receptor antagonist that might be beneficial i...
  • AhearneLawFirm_xarelto_eliquis_anticoagulant.jpg

    Blood thinners may improve survival among hospitalized COVID-19 patients

    8 May, 2020

    Research could change standard of care protocols to prevent clotting associated with coronavirus.

    Treating hospitalized COVID-19 patients with anticoagulants -- blood thinners that slow down clotting -- may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report. The study, published in the May 6 issue of the Journal of the American College of Cardiology, could provide new insight on how to treat and manage coronavirus patients once ...
  • Hydroxychloroquine-coronavirus-drug.jpg

    Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

    8 May, 2020
    Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.
    METHODS We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end po...
  • colorectal-lesion.jpg

    COVID‐19: Impact on Colorectal Surgery

    7 May, 2020
    AbstractThe rapid spread of the COVID‐19 pandemic created unprecedented challenges for the medical and surgical healthcare systems. With the ongoing need for urgent and emergency colorectal surgery including colorectal cancer surgeries, several questions pertaining to the operating room (OR) utilization and techniques needed to be rapidly addressed. Although patient safety is of paramount importance, caregiver safety is also a critical consideration. During the COVID‐19 pandemic, additional p...
  • unnamed.jpg

    Rapid development of an inactivated vaccine candidate for SARS-CoV-2

    7 May, 2020
    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which indu...
  • F_94029.jpg

    Skin protection for health care workers during COVID-19 epidemic must not be ignored

    7 May, 2020
    Since first reported in 2019, pneumonia associated with 2019 novel coronavirus disease (COVID‐19) has rapidly developed into an outbreak across the world. Number of the patients of all age groups has increased significantly. In order to curb the spread of the epidemic, thousands of health care workers (HCWs) have joined the front line of the fight against this highly contagious disease. When taking care of patients with COVID‐19 pneumonia, HCWs must first protect themselves by per...
  • descarga.png

    Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19

    6 May, 2020
    Coronavirus disease 2019 (COVID-19) was announced a pandemic by WHO on March 11, 2020. As of May 3, 2020, Italy is one of the countries hit hardest by the COVID-19 pandemic, with 28 884 confirmed deaths. In addition to pulmonary insufficiency, COVID-19 is associated with other life-threatening complications such as sepsis, heart failure, and pulmonary embolism. Here we describe patients with COVID-19 who presented with acute limb ischaemia but did not have atherosclerosis, atrial fibrillation...